SUMMARY The results of the Coulter counter S plus II platelet volume analysis were studied in 100
differentiation between these two causes of thrombocytosis can sometimes cause difficulties. Platelets from patients with myeloproliferative thrombocytosis may differ from those with reactive thrombocytosis in morphology, platelet volume distribution pattern, surface membrane composition, arachidonic acid metabolism, and granule content and function.2 From these the platelet volqme analysis can easily be performed in routine daily practice, as the modern fully automated blood cell counters produce comprehensive analysis on each whole blood sample that is processed. We therefore studied the efficiency of a platelet volume analysis using the Coulter S plus II and of the derived variables mean platelet volume (MPV) and platelet distribution width (PDW) for the differential diagnosis of thrombocytosis.
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The platelet volume analysis was made using a Coulter counter S plus II. Particles with a volume between 2 and 20 fl are classified by this instrument as platelets by definition, and a volume distribution histogram is generated and fitted to the nearest log normal curve.
From. this the platelet count, MPV, and PDW are computed.3 The PDW is calculated from the volumes on the 16th and 84th percentile.3
All measurements were made in whole blood anticoagulated with edetic acid. As it has been shown that edetic acid causes an increase in platelet volume during the first hour after collection, after which it remains stable for several hours,4 all measurements were made between one and six hours after the blood had been collected.
The histogram showing platelet volume distribution was plotted using a X-Y recorder. By measuring their relative surface area in the histogram we calculated the percentage of microthrombocytes and megathrombocytes. Microthrombocytes were arbitrarily defined as particles with a volume between 2 and 5 fl; 129 were studied. Diagnoses in these patients were: essential thrombocythaemia in 14; polycythaemia vera in 10; myelofibrosis in five; and chronic granulocytic leukaemia in one. Diagnoses were made according to the criteria of the polycythaemia vera study group.2 Thirty two patients with the same diagnoses, but with a platelet count between 150 and 500 x 109/l under our care during the same period were also studied. Twelve of these patients had polycythaemia vera, 10, essential thrombocythaemia, seven, chronic granulocytic leukaemia, and three, myelofibrosis. Most of them were treated, usually with busulphan; 18 had platelet counts above 500 x 109/l.
Platelet volumes were also studied in 100 consecutive patients with reactive thrombocytosis (platelet count > 500 x 109/1). These patients were traced by reviewing the results of all blood samples analysed by the Coulter counter over six weeks. The samples Van 
Results
Seventy three Coulter counter measurements were made from the 30 patients with myeloproliferative thrombocytosis, ranging from one to four per patient; and in the 32 patients with chronic myeloproliferative disease with a platelet count between 150 and 500 x 109/l 58 measurements were made (one to three per patient) ( Table 2) .
The mean platelet volume in patients with myeloproliferative thrombocytosis was significantly higher than that of the group with reactive thrombocytosis, although the overlap was considerable (Fig. 1 ). Normal subjects also had a much higher mean platelet volume than patients with reactive thrombocytosis. The mean platelet volume in the patients with myeloproliferative disease, both in those with a platelet count > 500 x 109/l and in those with a count between 150 and 500 x 109/1, did not differ from that found in normal subjects (Fig. 1) .
The opposite was true for platelet distribution width. There was no difference between normal subjects and patients with reactive thrombocytosis, but patients with myeloproliferative thrombocytosis and those with myeloproliferative disease and a platelet count between 150 and 500 109/1 had a considerably increased platelet distribution width (Fig. 2) . In only five patients with reactive thrombocytosis (5%) was a platelet distribution width > 17 found. Two of these patients had iron deficiency, two infection, and one colonic carcinoma with metastases. In the two (106) 852 ( (SD) . 0 indicates patients with chronic granulocytic leukaemia and myelofibrosis. * represents patients with essential thrombocythaemia and polycythaemia vera in groups with myeloproliferative disease. Platelet distribution width in patients with myeloproliferative disease is considerably higher than that in normal subjects and those with reactive thrombocytosis. 132 patients with iron deficiency and the one with infection the platelet distribution width fell below 17 after treatment. For the two other patients no follow up was available. On the other hand, in only eight of the 73 measurements in myeloproliferative thrombocytosis (four patients) was a platelet distribution width below 17 found (Fig. 2) . For platelet distribution width therefore, there was a much smaller overlap between reactive and myeloproliferative thrombocytosis than for mean platelet volume.
In the myeloproliferative groups there were no differences in mean platelet volume or platelet distribution width between patients with essential thrombocythaemia and polycythaemia vera and those with myelofibrosis or chronic granulocytic leukaemia (Figs. I and 2) . Table 2 shows the results of determining the percentage of microthrombocytes (2-5 fl) and megathrombocytes (13-20 fl) from the platelet volume distribution histogram. Compared with normal subjects the patients with reactive thrombocytosis and those with myeloproliferative disease had a substantially increased number of small platelets. The percentage of megathrombocytes in the patients with myeloproliferative disease was considerably greater than that in patients with reactive thrombocytosis, and was also greater, although not significantly so, than in normal subjects. The percentage of megathrombocytes in patients with reactive thrombocytosis was significantly lower than that in normal subjects ( Table 2 ). The overlap in the percentage of megathrombocytes between reactive and myeloproliferative thrombocytosis was greater than that found for platelet distribution width. Patients with reactive thrombocytosis also had an increased percentage of microplatelets but a lower number of megathrombocytes. This results in a norVan der Lelie, Von dem Borne mal platelet distribution width but a mean platelet volume that is lower than that found in normal subjects. This observation agrees with the findings of others.1 4 In normal subjects a non-linear inverse relation between platelet count and mean platelet volume has been found: the higher the platelet count, the lower the mean platelet volume.12 The low mean platelet volume in reactive thrombocytosis might be an extrapolation of this relation. Consequently, the mean platelet volume in myeloproliferative thrombocytosis, although not different from that in normal subjects, might still be abnormally increased.
Discussion
Although the mean platelet volume and the percentage of megathrombocytes in patients with myeloproliferative thrombocytosis were considerably higher than in patients with reactive thrombocytosis, these variables are of little clinical use in differential diagnosis because of the large overlap. The clinical importance of the platelet distribution width in this regard seems to be greater. Only five of the 100 patients with reactive thrombocytosis had a platelet distribution width > 17, whereas this was found in 26 of the 30 patients with myeloproliferative thrombocytosis. When a platelet distribution width > 17 was chosen as the dividing point the sensitivity and specificity for diagnosing myeloproliferative thrombocytosis was 87% and specificity 95%, respectively. The prevalence of myeloproliferative thrombocytosis was, however, much lower than that of reactive thrombocytosis. During the six weeks it took us to collect the 100 cases of reactive thrombocytosis no new myeloproliferative thrombocytosis was diagnosed. In analysing 372 cases of thrombocytosis Robbins and Barnard found a myeloproliferative disorder to be the cause in only 16%.' According to the theory of Bayes, this leads to a low positive predictive value.'3 With a prevalence of 1 6% the positive predictive value for myeloproliferative thrombocytosis of a platelet distribution width > 17 is only 22%. On the other hand, the negative predictive value is 99-8%.
In conclusion, an increased platelet heterogeneity is found not only in most patients with myeloproliferative thrombocytosis but also in patients who have chronic myeloproliferative disease and normal platelet counts. In reactive thrombocytosis platelet heterogeneity is only sporadically increased. A normal platelet distribution width in patients with a platelet count > 500 x 109/l strongly suggests reactive thrombocytosis.
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